NICE has recommended mirvetuximab soravtansine for women with folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer, opening the door to the first new NHS treatment for this form of the disease in more than two decades. The decision, announced on 4 June 2026, is aimed at patients whose cancer has stopped responding to standard chemotherapy within six months of treatment.
A targeted approach after years of limited options
The treatment, also known as Elahere and developed by AbbVie, uses a targeted therapy that seeks out a specific protein found on the surface of cancer cells and delivers a cancer-killing medicine directly to them. NICE said the therapy offers a new approach at a point when treatment options have been limited for women with this type of ovarian cancer.
According to NICE, women who took part in the evaluation highlighted the significant difference the two treatments can have on daily life. The recommendation marks a notable change in care for a group of patients who have faced particularly difficult choices after chemotherapy stops working.
Why the guidance matters for NHS care
The guidance is significant because it creates a new NHS option for people with a disease subtype that has historically been hard to treat. NICE said the medicine will be available for folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer, reflecting the organisation’s view that the clinical evidence supports its use in this setting.
The announcement also adds to a series of recent changes in cancer care guidance, but this specific recommendation stands apart because it is focused on a long-standing unmet need rather than a more routine update. For patients and clinicians, it represents a new pathway after many years in which standard chemotherapy remained the main option once the disease became resistant.
NICE’s full announcement can be read in its news release, while the corresponding guidance is available on the regulator’s website. ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-treatment-for-resistant-ovarian-cancer?utm_source=openai))
What happens next for patients
The decision is expected to shape access across the NHS as local services begin preparing for implementation. For women living with this diagnosis, the recommendation offers the prospect of a treatment designed specifically for a difficult-to-manage cancer subtype, rather than another round of conventional chemotherapy.
In practical terms, the move gives clinicians a new option to discuss with patients when disease progression leaves few alternatives. For families facing resistant ovarian cancer, that shift may be as important as the medicine itself.
